ISN Webinar: Dissemination and Implementation of Therapies for Kidney Diseases in Low- and High-Income Countries
Kidney protection by SGLT2 inhibitor is established now. However, the cost of the drug remains a problem. This issue is also applicable to other promising drugs for CKD and DKD. The ISN is trying to ensure equitable access to kidney care worldwide. However, implications of access to disease modifying drugs in low- and high-income countries remain serious issues. We believe that debate on the value proposition for low vs high income countries is important and useful.
1. Understand concepts of equitable access to kidney care
2. Understand health care economic tradeoffs in context of low and high income jurisdictions
3. Know value proposition of various therapeutic modalities for low vs high income countries
Luyckx VA, et al. Developing the ethical framework of end-stage kidney disease care: from practice to policy. Kidney Int Suppl (2011). 2020 Mar;10(1):e72-e77
Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018 Jun 1;96(6):414-422D.
Levin A, et al; ISN Global Kidney Health Summit participants. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017 Oct 21;390(10105):1888-1917